Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. j. med. biol. res ; 49(8): e5409, 2016. graf
Artigo em Inglês | LILACS | ID: lil-787387

RESUMO

Due to the presence of the renin-angiotensin system (RAS) in tissues and its specific influence on white adipose tissue, fat cells are possible targets of pharmacological RAS blockers commonly used as anti-hypertensive drugs. In the present study, we investigated the effects of different RAS blockers on fat cell metabolism, more specifically on lipolysis, lipogenesis and oxidation of energy substrates. Isolated primary adipocytes were incubated with different RAS blockers (aliskiren, captopril and losartan) in vitro for 24 h and lipolysis, lipogenesis and glucose oxidation capacities were determined in dose-response assays to a β-adrenergic agonist and to insulin. Although no change was found in lipolytic capacity, the RAS blockers modulated lipogenesis and glucose oxidation in a different way. While captopril decreased insulin-stimulated lipogenesis (−19% of maximal response and −60% of insulin responsiveness) due to reduced glucose derived glycerol synthesis (−19% of maximal response and 64% of insulin responsiveness), aliskiren increased insulin-stimulated glucose oxidation (+49% of maximal response and +292% of insulin responsiveness) in fat cells. Our experiments demonstrate that RAS blockers can differentially induce metabolic alterations in adipocyte metabolism, characterized by a reduction in lipogenic responsiveness or an increase in glucose oxidation. The impact of RAS blockers on adipocyte metabolism may have beneficial implications on metabolic disorders during their therapeutic use in hypertensive patients.


Assuntos
Animais , Masculino , Sistema Renina-Angiotensina/efeitos dos fármacos , Adipócitos/efeitos dos fármacos , Anti-Hipertensivos/farmacologia , Captopril/farmacologia , Ratos Wistar , Adipócitos/metabolismo , Losartan/farmacologia , Lipogênese/efeitos dos fármacos , Fumaratos/farmacologia , Amidas/farmacologia , Glucose/metabolismo , Glicerol/metabolismo , Lipólise/efeitos dos fármacos
2.
Braz. j. med. biol. res ; 47(3): 192-205, 03/2014. graf
Artigo em Inglês | LILACS | ID: lil-704621

RESUMO

Numerous studies address the physiology of adipose tissue (AT). The interest surrounding the physiology of AT is primarily the result of the epidemic outburst of obesity in various contemporary societies. Briefly, the two primary metabolic activities of white AT include lipogenesis and lipolysis. Throughout the last two decades, a new model of AT physiology has emerged. Although AT was considered to be primarily an abundant energy source, it is currently considered to be a prolific producer of biologically active substances, and, consequently, is now recognized as an endocrine organ. In addition to leptin, other biologically active substances secreted by AT, generally classified as cytokines, include adiponectin, interleukin-6, tumor necrosis factor-alpha, resistin, vaspin, visfatin, and many others now collectively referred to as adipokines. The secretion of such biologically active substances by AT indicates its importance as a metabolic regulator. Cell turnover of AT has also recently been investigated in terms of its biological role in adipogenesis. Consequently, the objective of this review is to provide a comprehensive critical review of the current literature concerning the metabolic (lipolysis, lipogenesis) and endocrine actions of AT.


Assuntos
Animais , Humanos , Camundongos , Ratos , Adipócitos/metabolismo , Adipogenia/fisiologia , Tecido Adiposo Branco/fisiologia , Lipólise/fisiologia , Obesidade/fisiopatologia , Adipocinas/metabolismo , Citocinas/metabolismo , Leptina/metabolismo , Nicotinamida Fosforribosiltransferase/metabolismo , Resistina/metabolismo , Transdução de Sinais/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA